Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer [Phase 1]

View source ↗

Summary

This Phase 1 study evaluates the efficacy and safety of CT041 in pancreatic cancer patients after adjuvant chemotherapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• CT041 (Claudin18.2-targeted CAR-T cell therapy)

Snippet

Sponsor: CARsgen Therapeutics Co., Ltd. | Conditions: Pancreatic Cancer | Phase 1 | Status: RECRUITING